Literature DB >> 33876358

Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.

Ryuichiro Sawada1, Takashi Akiyoshi2, Yusuke Kitagawa1, Yukiharu Hiyoshi1, Toshiki Mukai1, Toshiya Nagasaki1, Tomohiro Yamaguchi1, Tsuyoshi Konishi3, Noriko Yamamoto4, Masashi Ueno5, Yosuke Fukunaga1.   

Abstract

BACKGROUND: Previous studies have reported the utility of systemic inflammatory markers and CD8+ tumor-infiltrating lymphocyte (TIL) separately in predicting response to chemoradiotherapy (CRT) in rectal cancer; however, the efficacy of combining these markers remains unclear.
OBJECTIVE: This study aimed to elucidate the predictive efficacy of systemic inflammatory markers combined with CD8+ TIL density on response to neoadjuvant CRT in locally advanced rectal cancer.
METHODS: Ten systemic inflammatory markers and CD8+ TIL density were assessed in 267 patients with rectal cancer using pretreatment clinical data and biopsy samples. Response to CRT was determined using the Dworak tumor regression grade (TRG), with good responders classified as TRG3-4.
RESULTS: Receiver operating characteristic curve analysis showed high areas under the curve for the lymphocyte-to-C-reactive protein ratio (LCR) and neutrophil × monocyte (N × M) value (0.58 and 0.62, respectively). In the multivariate analysis, LCR, N × M value, and CD8+ TIL density were independently associated with good responders (p = 0.016, 0.005, and 0.002, respectively). Stratified analysis with these three markers showed a positive correlation between TRG3-4 ratio and the number of positive predictive factors (8.2%, 20.0%, 34.2%, and 59.1% in patients with 0, 1, 2, and 3 predictors, respectively). Overall and disease-free survival were significantly worse in patients with zero factors present compared with those with one to three factors present.
CONCLUSIONS: LCR, N × M value, and CD8+ TIL density are independently associated with response to CRT. Assessing local TIL density along with systemic inflammatory markers may be useful for selecting a multimodal neoadjuvant approach in rectal cancer therapy.

Entities:  

Year:  2021        PMID: 33876358     DOI: 10.1245/s10434-021-09975-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  47 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection.

Authors:  Tae Hyun Kim; Seung-Yong Jeong; Dong Hyun Choi; Dae Yong Kim; Kyung Hae Jung; Sung Ho Moon; Hee Jin Chang; Seok-Byung Lim; Hyo Seong Choi; Jae-Gahb Park
Journal:  Ann Surg Oncol       Date:  2007-12-05       Impact factor: 5.344

Review 3.  Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  S T Martin; H M Heneghan; D C Winter
Journal:  Br J Surg       Date:  2012-02-23       Impact factor: 6.939

4.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Authors:  Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets
Journal:  Lancet Oncol       Date:  2010-08-06       Impact factor: 41.316

5.  Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.

Authors:  Hee Chul Park; Nora A Janjan; Tito R Mendoza; Edward H Lin; Saroj Vadhan-Raj; Mandeep Hundal; Yiqun Zhang; Marc E Delclos; Christopher H Crane; Prajnan Das; Xin Shelley Wang; Charles S Cleeland; Sunil Krishnan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-21       Impact factor: 7.038

6.  Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.

Authors:  Joji Kitayama; Koji Yasuda; Kazushige Kawai; Eiji Sunami; Hirokazu Nagawa
Journal:  Radiat Oncol       Date:  2010-06-03       Impact factor: 3.481

7.  Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial.

Authors:  M Kusters; C A M Marijnen; C J H van de Velde; H J T Rutten; M J Lahaye; J H Kim; R G H Beets-Tan; G L Beets
Journal:  Eur J Surg Oncol       Date:  2010-01-21       Impact factor: 4.424

8.  Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.

Authors:  Angelita Habr-Gama; Joaquim Gama-Rodrigues; Guilherme P São Julião; Igor Proscurshim; Charles Sabbagh; Patricio B Lynn; Rodrigo O Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

9.  Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.

Authors:  Eisar Al-Sukhni; Kristopher Attwood; David M Mattson; Emmanuel Gabriel; Steven J Nurkin
Journal:  Ann Surg Oncol       Date:  2015-12-14       Impact factor: 5.344

10.  Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.

Authors:  Andre Konski; Tianyu Li; Elin Sigurdson; Steven J Cohen; William Small; Stewart Spies; Jian Q Yu; Andrew Wahl; Steven Stryker; Neal J Meropol
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-10       Impact factor: 7.038

View more
  1 in total

1.  Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density.

Authors:  Yao Xu; Xiaoying Lou; Yanting Liang; Zhenhui Li; Shenyan Zhang; Shangqing Yang; Qicong Chen; Zeyan Xu; Minning Zhao; Ke Zhao; Zaiyi Liu
Journal:  J Inflamm Res       Date:  2021-11-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.